Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders

  • George Diaz

Press/Media

Period8 Apr 2019

Media coverage

1

Media coverage

  • TitleAeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
    Media name/outletSpoke.com
    Country/TerritoryUnited States
    Date8/04/19
    URLwww.spoke.com/press_releases/5caa921c2c73fffcd9009b4a
    PersonsGeorge Diaz